Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Facing Flat Erbitux Sales, ImClone Talks Up Line Extension, Pipeline Promise

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm details plans to become “global, fully integrated, pure play antibody company” during 2007 sales and earnings call.

You may also be interested in...



ImClone Metastatic Breast Cancer Candidate Moves Into Phase III In Third Quarter

Firm sets progression-free survival as primary endpoint for 1,100-patient trial.

ImClone Metastatic Breast Cancer Candidate Moves Into Phase III In Third Quarter

Firm sets progression-free survival as primary endpoint for 1,100-patient trial.

ImClone/Bristol Aim To Expand Erbitux’s Reach To Asia

Development partners broker deal with Merck KGaA to bring the first EGFR receptor-inhibiting monoclonal antibody to Japan.

Related Content

Topics

UsernamePublicRestriction

Register

PS067214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel